Primary Ciliary Dyskinesia Market Insights: Epidemiology Trends, Pipeline Advances, and Forecast Growth to 2034: DelveInsight | Parion Sciences, Recode Therapeutics, Ethris, Cila Therapeutics

DelveInsight's latest report on Primary Ciliary Dyskinesia (PCD) forecasted significant growth in the PCD market, driven by improved diagnostic methods, a rising prevalence of the disease, and the expected entry of novel therapies such as P-1037 IS/VX-371 (PARION SCIENCES), RCT1100 (RECODE THERAPEUTICS), ETH 42 (ETHRIS GmbH), CIL-05 (CILA THERAPEUTICS), and others.

DelveInsight's latest "Primary Ciliary Dyskinesia Market Insight, Epidemiology and Market Forecast" report combines robust epidemiological data with market trends, competitive landscape analysis, and patient journey assessments. The report forecasts that the market size for Primary Ciliary Dyskinesia (PCD) in 7MM, which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, is expected to increase from approximately USD 101 million in 2023 over the next 10 years. Among the 7MM, the US market is expected to rise at a significant CAGR from approximately USD 36 million in 2023. This growth is attributed to increased awareness, improved screening and diagnosis rates, a rising prevalence of the disease, and the anticipated introduction of emerging therapies.

Download the Primary Ciliary Dyskinesia Market report to understand which factors are driving the primary ciliary dyskinesia therapeutic market @ https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The report also offers an in-depth epidemiological analysis and forecasts up to 2034, segmented by Primary Ciliary Dyskinesia prevalent cases, Primary Ciliary Dyskinesia diagnosed prevalent cases, age-specific cases, Primary Ciliary Dyskinesia prevalence by pathogenic variants in genes, and Primary Ciliary Dyskinesia prevalent cases by clinical manifestations across the 7MM. According to research conducted by DelveInsight's analysts, the general prevalence of PCD is reported to be between 1 in 11,000 and 1 in 16,000 live births, although the actual prevalence may be higher. In the UK, the prevalence is estimated to be 1 in 7,500, with about 3,000 diagnosed prevalent cases. The US, on the other hand, has nearly 1,800 diagnosed prevalent cases in 2023 out of ~70,000 total diagnosed prevalent cases of PCD in 7MM. It has also been observed that children aged 6 to 20 years account for the highest number of cases, particularly in the United States, and this trend is expected to continue during the forecast period.

Discover evolving trends in the primary ciliary dyskinesia patient pool forecasts @ https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

DelveInsight's analysis reveals that a decent number of companies are launching clinical trials to investigate new treatment options or improve existing ones. The clinical development pipeline includes drugs such as P-1037 IS/VX-371 (PARION SCIENCES), RCT1100 (RECODE THERAPEUTICS), ETH 42 (ETHRIS GmbH), CIL-05 (CILA THERAPEUTICS), among others.

As there is currently no standard treatment for PCD, the focus remains on managing respiratory symptoms, preventing infections, opening airways, and reducing inflammation through antibiotics, bronchodilators, or anti-inflammatory medications. This emphasises the potential of emerging diagnoses and therapies to revolutionise the treatment landscape for PCD.

Among the anticipated emerging therapies, RCT1100 by ReCode Therapeutics, an inhaled mRNA-based investigational therapy, shows promising results in restoring ciliary function in the lungs, addressing the root cause of PCD rather than merely controlling symptoms. The report provides a detailed analysis of the anticipated uptake rates for the potential PCD drugs expected to launch between 2025 and 2034.

Recent developments, including the US FDA's Orphan Drug Designation (ODD) for RCT1100 by ReCode Therapeutics in June 2024, along with significant clinical trial updates for TH 42 (ETHRIS GmbH) and CIL-05 (CILA THERAPEUTICS), emphasise the momentum in the field.

Unlock which primary ciliary dyskinesia emerging drug is expected to capture the largest market share in 7MM by 2034. Visit https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Although PCD presents significant challenges due to its frequent misidentification as a more common respiratory disorder, potentially leading to an underreporting of its true prevalence and significant delays in treatment, the emergence of improved diagnostic methods and novel therapies is set to broaden treatment options and spur market growth.

Scope of the Primary Ciliary Dyskinesia Market Report

Study Period: 2020-2034
Coverage: 7MM [The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key Primary Ciliary Dyskinesia Companies
Key Primary Ciliary Dyskinesia Therapies
Primary Ciliary Dyskinesia Therapeutic Assessment: Primary Ciliary Dyskinesia current marketed and Primary Ciliary Dyskinesia emerging therapies
Primary Ciliary Dyskinesia Market Dynamics: Primary Ciliary Dyskinesia market drivers and Primary Ciliary Dyskinesia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Primary Ciliary Dyskinesia Unmet Needs, KOL's views, Analyst's views, Primary Ciliary Dyskinesia Market Access and Reimbursement

Table of contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Primary Ciliary Dyskinesia Market Overview at a Glance
5. Epidemiology and Market Forecast Methodology
6. Key Events
7. Primary Ciliary Dyskinesia Background and Overview
8. Primary Ciliary Dyskinesia Treatment
9. Primary Ciliary Dyskinesia Epidemiology and Patient Population in the 7MM
10. Primary Ciliary Dyskinesia Patient Journey
11. Primary Ciliary Dyskinesia Marketed Drug
12. Primary Ciliary Dyskinesia Emerging Drugs
13. Primary Ciliary Dyskinesia: 7MM Analysis
14. Unmet needs
15. SWOT Analysis
16. KOL Views
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

This release was published on openPR.